Novartis sells eye business to Bausch+Lomb for $2.5 billion
HQ Team July 3, 2023: Swiss drugmaker Novartis is divesting its ophthalmology assets including Xiidra, an anti-inflammatory eye drop to Bausch + Lomb,.
Drugs
Medical
Pharma